國立虎尾科技大學 |

Innovations for Next-Generation Antibody-Drug Conjugates

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Innovations for Next-Generation Antibody-Drug Conjugates/ edited by Marc Damelin.
其他作者:	Damelin, Marc.
面頁冊數:	VIII, 357 p. 70 illus., 52 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Cancer research. -
電子資源:	https://doi.org/10.1007/978-3-319-78154-9
ISBN:	9783319781549

Innovations for Next-Generation Antibody-Drug Conjugates
Innovations for Next-Generation Antibody-Drug Conjugates[electronic resource] /edited by Marc Damelin. - 1st ed. 2018. - VIII, 357 p. 70 illus., 52 illus. in color.online resource. - Cancer Drug Discovery and Development,2196-9906. - Cancer Drug Discovery and Development,.

Chapter 1 Introduction: Motivations for Next-Generation ADCs -- Chapter 2 Combining ADCs with Immuno-oncology Agents -- Chapter 3 Improving the Safety Profile of ADCs -- Chapter 4 Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development -- Chapter 5 Regulatory Considerations and Companion Diagnostics -- Chapter 6 ADC Process Development and Manufacturing -- Chapter 7 HER2-Targeted ADCs: At the forefront of ADC technology development -- Chapter 8 Next generation payloads for ADCs -- Chapter 9 Delivering more payload: High DAR ADCs -- Chapter 10 Site-Specific Antibody Drug Conjugates -- Chapter 11 Bispecific and Biparatopic Antibody-Drug Conjugates -- Chapter 12 drug conjugates to the tumor microenvironment: Probody Drug Conjugates -- Chapter 13 Antibody-Drug Conjugates: Targeting the Tumor Microenvironment -- Chapter 14 Next Horizons: ADCs Beyond Oncology.

Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.

ISBN: 9783319781549

Standard No.: 10.1007/978-3-319-78154-9doiSubjects--Topical Terms:

1253664
Cancer research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Innovations for Next-Generation Antibody-Drug Conjugates
LDR:03566nam a22004095i 4500 001 994079
003 DE-He213
005 20200629200109.0
007 cr nn 008mamaa
008 201225s2018 gw | s |||| 0|eng d
020 $a 9783319781549 $9 978-3-319-78154-9
024 7 $a 10.1007/978-3-319-78154-9 $2 doi
035 $a 978-3-319-78154-9
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Innovations for Next-Generation Antibody-Drug Conjugates $h [electronic resource] / $c edited by Marc Damelin.
250 $a 1st ed. 2018.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Humana, $c 2018.
300 $a VIII, 357 p. 70 illus., 52 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Cancer Drug Discovery and Development, $x 2196-9906
505 0 $a Chapter 1 Introduction: Motivations for Next-Generation ADCs -- Chapter 2 Combining ADCs with Immuno-oncology Agents -- Chapter 3 Improving the Safety Profile of ADCs -- Chapter 4 Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development -- Chapter 5 Regulatory Considerations and Companion Diagnostics -- Chapter 6 ADC Process Development and Manufacturing -- Chapter 7 HER2-Targeted ADCs: At the forefront of ADC technology development -- Chapter 8 Next generation payloads for ADCs -- Chapter 9 Delivering more payload: High DAR ADCs -- Chapter 10 Site-Specific Antibody Drug Conjugates -- Chapter 11 Bispecific and Biparatopic Antibody-Drug Conjugates -- Chapter 12 drug conjugates to the tumor microenvironment: Probody Drug Conjugates -- Chapter 13 Antibody-Drug Conjugates: Targeting the Tumor Microenvironment -- Chapter 14 Next Horizons: ADCs Beyond Oncology.
520 $a Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.
650 0 $a Cancer research. $3 1253664
650 0 $a Molecular biology. $3 583443
650 1 4 $a Cancer Research. $3 668358
650 2 4 $a Molecular Medicine. $3 668353
700 1 $a Damelin, Marc. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1205309
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319781532
776 0 8 $i Printed edition: $z 9783319781556
776 0 8 $i Printed edition: $z 9783030086275
830 0 $a Cancer Drug Discovery and Development, $x 2196-9906 $3 1253870
856 4 0 $u https://doi.org/10.1007/978-3-319-78154-9
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)